# Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Source: https://onco.cc/trials/nct07500220/  
OnCo record `nct07500220` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine, Cyclophosphamide in hepatocellular carcinoma, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC is a phase 1/2 interventional study registered as NCT07500220 by Beijing Biotech, with 30 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide. Conditions listed: Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07500220
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation and Dose-Expansion Study of Allogeneic Dual-Target GPC3/B7-H3 (CD276) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Relapsed/Refractory, or Metastatic Hepatocellular Carcinoma
- Sponsor: Beijing Biotech
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07500220: https://clinicaltrials.gov/study/NCT07500220

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07500220.json